ox +

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

	Complete if Known
Application Number	09/891,206
Filing Date	June 26, 2001
First Named Inventor	ATHERTON et al.
Group Art Unit	1616
Examiner Name	Unassigned PAK, J.
Attorney Docket Number	PHARMA-131

\rightarrow							
S					U.S. PATENT DOCUM	MENTS	
1.4	xaminer nitials *	Cite No.1	U.S. Patent Docu Number Kind C	Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
42	7)	1	5,342,604		Wilson et al.	08-30-1994	
	n e	2	5,714,631		Wilson et al.	02-03-1998	
	M	3	5,902,825		Wei Jia	05-11-1999	
	2	4	5,968,976		Murrer et al.	10-19-1999	
		5	6,027,737		Morris, Jr. et al.	02-22-2000	
Ľ	<i>"</i>						
							E s M
	**						
							Z
L							<u> </u>
					-		600/290C
							0 2 1
L							
				ļ			
				<u> </u>			
						£	

				FOR	EIG	N PATENT DOCU	MENTS		
F		Fore	eign Patent Do	ocument		Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No. ¹	Office ³	Number⁴	Kind Co		or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₆
CO)2	6	WIPO	WO 96/3	0029			10-03-1996		
91	7	FR	2 493 7	704			11-07-1980		
·				-					
	· · · · · · · · · · · · · · · · · · ·								

Examiner Signature	Jobsen	Date Considered	1/20/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

18

19

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute fo	or form 1449A/PTO			Compl te if Known			
MEA	SEATION			Application Number	09/891,206		
			CLOSURE	Filing Date June 26, 2001			
STATE	EMENT B	YAI	PPLICANT	First Named Inventor ATHERTON et al.			
				Group Art Unit	1616		
(L	ise as many she	ets as	necessary)	Examiner Name	Unassigned— PAK, J.		
Sheet	2	of	2	Attorney Docket Number	PHARMA-131		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² xaminer Initials * Cite the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. No. Fernandez-GAVARRON et al., "Incorporation of 140-lanthanum into bones, teeth and hydroxyapatite", Bone and Mineral 3, 1998, pp. 283-291 YANAGIHARA et al., "Synthesis of Lanthanide Carbonates", <u>Journal of the Less-Common Metals</u>, 167: 1991, pp 223-232 Guggino et al., "Bone remodeling signaled by a dihydropyridine- and phenylalkylamine-sensitive calcium channel", 10 Proc. Natl. Acad. Sci., 86:April 1999, pp. 2957-2960 GRAFF et al., "A Possible Non-aluminum oral phosphate binder? A Comparative Study on Dietary Phosphorus Absorption", Reseach Communications in Molecular Pathology and Pharmacology, Sep. 1995, pp, 373-388, Vol 11 89. No. 3 HERGESELL et al., Phosphate binders on iron basis: A new perspective?", Kidney International, 1999, pp. S-42-12 S-45, Vol. 56., Suppl. 73 HUTCH SON et al., "Calcitrol, Lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy", <u>Procedings of the ISPD '98 - The Vilith Congress of the ISPD</u>, August 28-26, 1998, pp. S408-S412 13 KARPINSKI et al. " A dihydropyridine-Sensitive Calciu um Channel in Rodent Osteoblastie Celle", Calcif Tissue Int. 45: 1989; pp 54:97; J. MCCLURE et al., "The production of Calcification in connective Tissue and Skeletal Muscle Using Various 15 Chemical Compounds", Calicif Tiss. Res., 22: 1976, pp.129-135 SHANKAR et al., "Activation and inactivation of the osteoclast Ca^{2*} receptor by the trivalent cation, La^{3*}, Biochemicaland Biophysical Research Communications, 187 (2): Sep. 16, 1992, pp 907-912 16 ZIMMERMANN et al., "Inhibition of chondrogenesis and endochrondral mineralization in vitro by different calcium 17 channel blockers", European Journal of Cell Biology, 1994, pp. 114-121, Vol 63

Signature Considered 7 20/05	I Signature I	() full ! m	Date Considered	1/20/03
------------------------------	---------------	--------------	--------------------	---------

Harris et al., "The Effect of Lanthanum Chloride and related Compounds on Calcification", Arch. int. Pharmacodyn.

1970, pp. 269-278, Vol. 186 DOTY et al., "Morphological Evidence of gap Junctions Between Bone Cells", Calcif. Tissue Int., 1981, pp 509-

512, Vol. 33

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAY 1 0 2002 TECH CENTER 1600/2900

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A	'08-00\
F I O/JB/OOM	00-00

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Caperwork Rental of 1995, no persons	; are required to respond to a collection	of information unless it contains a valid OMB	control number
Substitute for form 1449A/PTO		Complete if Known	
INFORMATION BIGGLOGUES	Application Number	09/891,206	
INFORMATION DISCLOSURE	Filing Date	June 26, 2001	
STATEMENT BY APPLICANT	First Named Inventor	ATHERTON et al.	
	Group Art Unit	1616	

First Named Inventor ATHERTON et al.

Group Art Unit 1616

(use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number PHARMA-131

ign (+) inside this box

Please type a plus

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
M	AA	R.H. WASSERMAN et al., "Effect of Vitamin D ₃ on Lanthanum Absorption: Suggestive Evidence for a Shunt Path", <u>Calcium Metab. Bone Metab.</u> , <u>Bone Dis.</u> , <u>Proc. Eur. Symp. Calcif. Tissues 10th</u> , 1975, pp. 87-90	
M	АВ	International Search Report dated May 17, 2002	
		RECEIVED	
		HI 1 2002	
		JUL 1 1 2002	,
		TECH CENTER 1600/2	900
		·	

Examiner Signature	Spanh	Date Considered	1/20/03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.